Showing 2301-2310 of 2894 results for "".
- Thermage® FLX Exceeds 5 Million Skin Tightening Treatmentshttps://modernaesthetics.com/news/thermage-flx-exceeds-5-million-skin-tightening-treatments/2483284/Solta Medical, a subsidiary of Bausch Health Companies Inc., announced that more than 5 million Thermage® treatments have been performed worldwide, underscoring the global uptake of its skin tightening technology. Thermage® uses monopolar radiofrequency energy to heat skin layers and stimu
- Revance Brings Mepivacaine-Based Fillers to US Markethttps://modernaesthetics.com/news/revance-brings-mepivacaine-based-fillers-to-us-market/2483155/Revance has announced the US launch of the Teoxane RHA® Collection with Mepivacaine, marking a significant innovation in dermal filler formulations. The update reflects a shift in anesthetic agents used in hyaluronic acid fillers, with mepivacaine replacing lidocaine as the primary ane
- Device Manufacturer’s Initiative Offers Treatments to Support Firefighters’ Healthhttps://modernaesthetics.com/news/device-manufacturers-initiative-offers-treatments-to-support-firefighters-health/2483123/BTL Industries has launched a nationwide initiative aimed at addressing the mental and physical health challenges faced by firefighters, particularly those serving in high-risk wildfire regions. The program is framed under BTL’s Heros Deserve Healing campaign, which calls on clinicians an
- Amarte Relaunches Dermatologist-Formulated Ultra Veil Daily SPF 40https://modernaesthetics.com/news/amarte-relaunches-dermatologist-formulated-ultra-veil-daily-spf-40/2483103/Amarte Skin Care has relaunched its flagship sunscreen, ULTRA VEIL® DAILY SPF 40, according to a press release from the manufacturer. The updated product maintains its position as a top-tier hybrid sunscreen, the press release
- Korean Skincare Brand Launches in US with Sensitive-Skin Formulationshttps://modernaesthetics.com/news/korean-skincare-brand-launches-in-us-with-sensitive-skin-formulations/2483054/South Korean skincare brand Hexkin has entered the US market, offering products formulated for sensitive skin using collagen-based and peptide-driven technologies, according to a press release. Rooted in traditional Korean sk
- New Website Streamlines Laser Therapy Device Selectionhttps://modernaesthetics.com/news/new-website-streamlines-laser-therapy-device-selection/2482984/ColdLasers.org has launched LaserTherapy.com, a redesigned platform aimed at simplifying the process of selecting therapeutic laser devices. The site offers a modern interface, comparison tools, and updated educational content designed to support informed decision-making. The platform addr
- JUVÉDERM Day Returns with Limited-Time Offers Through Rewards Programhttps://modernaesthetics.com/news/juvederm-day-returns-limited-time-offers-through-rewards-program/2482957/Members of JUVÉDERM’s Alle loyalty rewards program will have an opportunity to purchase “buy one, get one” gift cards as part of JUVÉDERM Day on August 20, according to Allergan Aesthetics, an AbbVie company. Details of the exclusive, limited limited-time offers are as follows: •
- Study: Aesthetic Surgeries Rise Among GLP-1 RA Patientshttps://modernaesthetics.com/news/study-aesthetic-surgeries-rise-among-glp-1-ra-patients/2476139/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in the Aesthet
- Alma Introduces PixelPeel™ Laser Peel for Minimal-Downtime Skin Renewalhttps://modernaesthetics.com/news/alma-introduces-pixelpeel-laser-peel-for-minimal-downtime-skin-renewal/2476137/Alma has launched PixelPeel™, a new fractional laser peel treatment designed for subtle, controlled skin resurfacing with minimal recovery time. The treatment is compatible with the Alma Pixel™ and Alma Hybrid® platforms and uses the company’s MotionSync™ technology to deliver uniform exfoliation
- AMI Pharm Advances AYP-101 to Phase 3 Testing for Noninflammatory Fat Reductionhttps://modernaesthetics.com/news/ami-pharm-advances-ayp-101-to-phase-3-testing-for-noninflammatory-fat-reduction/2476093/AMI Pharm has initiated a pivotal Phase 3 clinical trial of AYP-101, an investigational injectable for the treatment of submental fat. The study will evaluate the efficacy and safety of the agent, which is designed to reduce localized fat with fewer inflammatory side effects than current therapie